Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Major Depressive Disorder
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
This is a phase 4, multicenter, open-label, flexible dose trial designed to assess the effects of brexpiprazole (flexible dose; 0.5 to 2 mg QD) as adjunctive therapy to ADT on life engagement in patients with MDD. This trial is being conducted in line with the Canadian Product Monograph.
This is a phase 4, multicenter, open-label, flexible dose trial designed to assess the effects of brexpiprazole (flexible dose; 0.5 to 2 mg QD) as adjunctive therapy to ADT on life engagement in patients with MDD. This trial is being conducted in line with the Canadian Product Monograph.
Tracking Information
- NCT #
- NCT04830215
- Collaborators
- Lundbeck Canada Inc.
- Otsuka Canada Pharmaceutical Inc.
- Investigators
- Study Director: Eva Kohegyi, MD Otsuka Pharmaceutical Development & Commercialization, Inc.